Jing-Jing Li

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Venues

Nature medicine

Oncogene

The Journal of cell biology

Cell death and differentiation

This page only lists publications with an associated author ORCID identifier.

Publications

Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine 30 (3) (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Ying-Yi Qin, Jie Shi, Wei-Xing Guo, Chong-De Lu, Ya-Xin Zheng, Fei-Guo Zhou, Mao-Lin Yan, Hong-Kun Zhou, Chao Liang, Fan Zhang, Wen-Jing Wei, Wan Yee Lau, Jing-Jing Li, Yan-Fang Liu, Shu-Qun Cheng
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature medicine (2024)
Qian-Wen Zheng, Qian-Zhi Ni, Bing Zhu, Xin Liang, Ning Ma, Yi-Kang Wang, Sheng Xu, Hui-Jun Cao, Ji Xia, Feng-Kun Zhang, Er-Bin Zhang, Xiao-Song Qiu, Xu-Fen Ding, Lin Qiu, Xi-Lin Zhang, Zhao-Hui Dong, Zhi-Gang Li, Xue-Li Zhang, Dong Xie, Jing-Jing Li
Correction to: PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3. Oncogene (2023)
Ji Xia, Ning Ma, Qian Shi, Qin-Cheng Liu, Wei Zhang, Hui-Jun Cao, Yi-Kang Wang, Qian-Wen Zheng, Qian-Zhi Ni, Sheng Xu, Bing Zhu, Xiao-Song Qiu, Kai Ding, Jing-Yi Huang, Xin Liang, Yu Chen, Yan-Jun Xiang, Xi-Ran Zhang, Lin Qiu, Wei Chen, Dong Xie, Xiang Wang, Lingyun Long, Jing-Jing Li
XAF1 promotes colorectal cancer metastasis via VCP-RNF114-JUP axis. The Journal of cell biology 223 (2) (2023)
Qian-Wen Zheng, Qian-Zhi Ni, Bing Zhu, Xin Liang, Ning Ma, Yi-Kang Wang, Sheng Xu, Hui-Jun Cao, Ji Xia, Feng-Kun Zhang, Er-Bin Zhang, Xiao-Song Qiu, Xu-Fen Ding, Lin Qiu, Xi-Lin Zhang, Zhao-Hui Dong, Zhi-Gang Li, Xue-Li Zhang, Dong Xie, Jing-Jing Li
PPDPF promotes lung adenocarcinoma progression via inhibiting apoptosis and NK cell-mediated cytotoxicity through STAT3. Oncogene 41 (36) (2022)
Hui-Jun Cao, Hao Jiang, Kai Ding, Xiao-Song Qiu, Ning Ma, Feng-Kun Zhang, Yi-Kang Wang, Qian-Wen Zheng, Ji Xia, Qian-Zhi Ni, Sheng Xu, Bing Zhu, Xu-Fen Ding, Tian-Wei Chen, Lin Qiu, Wei Chen, Zhi-Gang Li, Bin Zhou, Wen-Ming Feng, Dong Xie, Jing-Jing Li
ARID2 mitigates hepatic steatosis via promoting the ubiquitination of JAK2. Cell death and differentiation (2022)
Qian-Wen Zheng, Xu-Fen Ding, Hui-Jun Cao, Qian-Zhi Ni, Bing Zhu, Ning Ma, Feng-Kun Zhang, Yi-Kang Wang, Sheng Xu, Tian-Wei Chen, Ji Xia, Xiao-Song Qiu, Dian-Zhen Yu, Dong Xie, Jing-Jing Li
Ochratoxin A Induces Steatosis via PPARγ-CD36 Axis. Toxins 13 (11) (2021)
Ning Ma, Yi-Kang Wang, Sheng Xu, Qian-Zhi Ni, Qian-Wen Zheng, Bing Zhu, Hui-Jun Cao, Hao Jiang, Feng-Kun Zhang, Yan-Mei Yuan, Er-Bin Zhang, Tian-Wei Chen, Ji Xia, Xu-Fen Ding, Zhen-Hua Chen, Xiu-Ping Zhang, Kang Wang, Shu-Qun Cheng, Lin Qiu, Zhi-Gang Li, Yong-Chun Yu, Xiao-Fan Wang, Bin Zhou, Jing-Jing Li, Dong Xie
PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling. Nature communications 12 (1) (2021)
Er-Bin Zhang, Xiuping Zhang, Kang Wang, Fengkun Zhang, Tian-Wei Chen, Ning Ma, Qian-Zhi Ni, Yi-Kang Wang, Qian-Wen Zheng, Hui-Jun Cao, Ji Xia, Bing Zhu, Sheng Xu, Xufen Ding, Xiang Wang, Zhigang Li, Shu-Qun Cheng, Dong Xie, Jing-Jing Li
Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis. Oncogene 40 (34) (2021)

Jing-Jing Li.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jing-Jing Li